Reference

New drug targeting treatment - Glivec

New drug targeting treatment - Glivec. Sun, Xue-mei; Brady, Ben (Nanjing Drum Tower Hospital, Nanjing University Medical College, Nanjing 210008, Peop. Rep. China). Chinese Journal of Cancer Research, 15(3), 235-239 (English) 2003 Chinese Journal of Cancer Research. CODEN: CJCRFH. 138238-67-2 and 220127-57-1 are cas registry numbers. These chemicals are also mentioned in this article. ISSN: 1000-9604. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. This review evaluates the role of Glivec in the treatment of chronic myelogenous leukemia and other malignant tumors. Preclin. and clin. evidence showed that Glivec demonstrated a potent and specific inhibition on BCR-ABL pos. leukemias and other malignant tumors in which overexpression of c-kit and PDGFR-b played a major role in their pathogenesis. Glivec has induced complete hematol. responses in up to 98% of patients evaluated in clin. trials. It is a very successful drug that supported the idea of targeted therapy through inhibition of tyrosine kinases. Although it is still in the early stages of clin. development and the resistance to Glivec remains to be a problem needed further study, a great deal has been learned from these research and observation. And with the increasing data, mol. targeting therapy will play much more important role in the treatment of malignant tumors. With the better understanding of the pathogenesis of malignant tumors, well-designed drugs targeting the specific mol. abnormalities with higher efficacy and lower side effect will benefit numerous patients with malignant tumors. .

Imatinib for small cell lung cancer, aiming for a target in vivo

Imatinib for small cell lung cancer, aiming for a target in vivo. Johnson, Bruce E. (Dana-Farber Cancer Institute and the Departments of Medicine, Department of Medical Oncology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA). Clinical Cancer Research, 10(10), 3235-3236 (English) 2004 American Association for Cancer Research. CODEN: CCREF4. ISSN: 1078-0432. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. The research of Wolff et al. (2004) entitled "Imatinib mesylate efficiently achieves therapeutic intratumor concns. in vivo, but has limited activity in a model of small cell lung cancer" is reviewed with commentary and refs. Using cell lines NCI-H209, H526, and H1607, Wolff et al. show the in vivo growth of small cell lung cancer is not inhibited by the oral administration of imatinib. The initial clin. data has shown that there is no obvious evidence of antitumor activity in a small Phase II trial with imatinib for patients with small cell lung cancer. Wolff et al. also provide addnl. evidence that further testing with in vivo studies targeted agents directed against receptors without activating mutations may be helpful in developing the rationale before embarking on an expensive, time consuming, and potentially ineffective clin. trials.Except for chemicals metioned above, 220127-57-1 is also used. .